Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
BörsenkürzelQTRX
Name des UnternehmensQuanterix Corp
IPO-datumDec 07, 2017
CEOToloue (Masoud)
Anzahl der mitarbeiter471
WertpapierartOrdinary Share
GeschäftsjahresendeDec 07
Addresse900 Middlesex Turnpike
StadtBILLERICA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01821
Telefon16173019400
Websitehttps://www.quanterix.com/
BörsenkürzelQTRX
IPO-datumDec 07, 2017
CEOToloue (Masoud)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten